Literature DB >> 28911152

Hypothalamic Glucose Transport in Humans During Experimentally Induced Hypoglycemia-Associated Autonomic Failure.

Elizabeth R Seaquist1, Amir Moheet1, Anjali Kumar1, Dinesh K Deelchand2, Melissa Terpstra2, Kristine Kubisiak3, Lynn E Eberly3, Pierre-Gilles Henry2, James M Joers2, Gülin Öz2.   

Abstract

Context: Upregulated brain glucose transport in response to recurrent hypoglycemia may contribute to the development of hypoglycemia-associated autonomic failure (HAAF) and impaired awareness of hypoglycemia. Whether recurrent hypoglycemia alters glucose transport in the hypothalamus is unknown. Objective: To test the hypothesis that hypothalamic glucose transport will increase in healthy volunteers preconditioned with recurrent hypoglycemia to induce HAAF. Setting: University medical center. Design and Participants: Thirteen healthy subjects underwent paired euglycemic and hypoglycemic preconditioning studies separated by at least 1 month. Following preconditioning, hypothalamic glucose transport was measured by magnetic resonance spectroscopy (MRS) in the afternoon on day 2 of each preconditioning protocol. Outcome Measure: The ratio of maximal transport rate to cerebral metabolic rate of glucose (Tmax/CMRglc), obtained from MRS-measured glucose in the hypothalamus as a function of plasma glucose.
Results: HAAF was successfully induced based on lower epinephrine, glucagon, and cortisol during the third vs first hypoglycemic preconditioning clamp (P ≤ 0.01). Hypothalamic glucose transport was not different following recurrent euglycemia vs hypoglycemia (Tmax/CMRglc 1.62 ± 0.09 after euglycemia preconditioning and 1.75 ± 0.14 after hypoglycemia preconditioning; P was not significant). Hypothalamic glucose concentrations measured by MRS were not different following the two preconditioning protocols. Conclusions: Glucose transport kinetics in the hypothalamus of healthy humans with experimentally induced HAAF were not different from those measured without HAAF. Future studies of patients with diabetes and impaired awareness of hypoglycemia will be necessary to determine if the existence of the diabetes state is required for this adaptation to hypoglycemia to occur.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28911152      PMCID: PMC5587056          DOI: 10.1210/jc.2017-00477

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  Field mapping without reference scan using asymmetric echo-planar techniques.

Authors:  R Gruetter; I Tkác
Journal:  Magn Reson Med       Date:  2000-02       Impact factor: 4.668

2.  Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem.

Authors:  Gülin Oz; Ivan Tkáč
Journal:  Magn Reson Med       Date:  2010-11-30       Impact factor: 4.668

3.  Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [11C]-3-O-methyl-D-glucose PET study.

Authors:  E M Bingham; J T Dunn; D Smith; J Sutcliffe-Goulden; L J Reed; P K Marsden; S A Amiel
Journal:  Diabetologia       Date:  2005-09-06       Impact factor: 10.122

4.  Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms.

Authors:  D A Towler; C E Havlin; S Craft; P Cryer
Journal:  Diabetes       Date:  1993-12       Impact factor: 9.461

5.  Patients with type 1 diabetes exhibit altered cerebral metabolism during hypoglycemia.

Authors:  Kim C C van de Ven; Cees J Tack; Arend Heerschap; Marinette van der Graaf; Bastiaan E de Galan
Journal:  J Clin Invest       Date:  2013-01-09       Impact factor: 14.808

6.  Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

7.  Differentiation of glucose transport in human brain gray and white matter.

Authors:  R A de Graaf; J W Pan; F Telang; J H Lee; P Brown; E J Novotny; H P Hetherington; D L Rothman
Journal:  J Cereb Blood Flow Metab       Date:  2001-05       Impact factor: 6.200

8.  Brain glucose concentrations in patients with type 1 diabetes and hypoglycemia unawareness.

Authors:  Amy B Criego; Ivan Tkac; Anjali Kumar; William Thomas; Rolf Gruetter; Elizabeth R Seaquist
Journal:  J Neurosci Res       Date:  2005 Jan 1-15       Impact factor: 4.164

9.  Comparison of arterialized venous sampling from the hand and foot in the assessment of in vivo glucose metabolism.

Authors:  E R Seaquist
Journal:  Metabolism       Date:  1997-11       Impact factor: 8.694

10.  Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans.

Authors:  Benjamin A Cooperberg; Philip E Cryer
Journal:  Diabetes Care       Date:  2009-09-03       Impact factor: 17.152

View more
  10 in total

1.  Advanced single voxel 1 H magnetic resonance spectroscopy techniques in humans: Experts' consensus recommendations.

Authors:  Gülin Öz; Dinesh K Deelchand; Jannie P Wijnen; Vladimír Mlynárik; Lijing Xin; Ralf Mekle; Ralph Noeske; Tom W J Scheenen; Ivan Tkáč
Journal:  NMR Biomed       Date:  2020-01-10       Impact factor: 4.044

2.  Differential Resting State Connectivity Responses to Glycemic State in Type 1 Diabetes.

Authors:  Lisa Parikh; Dongju Seo; Cheryl Lacadie; Renata Belfort-Deaguiar; Derek Groskreutz; Muhammad Hamza; Feng Dai; Dustin Scheinost; Rajita Sinha; R Todd Constable; Robert Sherwin; Janice Jin Hwang
Journal:  J Clin Endocrinol Metab       Date:  2020-01-01       Impact factor: 5.958

3.  Glycemic Variability and Brain Glucose Levels in Type 1 Diabetes.

Authors:  Janice J Hwang; Lihong Jiang; Elizabeth Sanchez Rangel; Xiaoning Fan; Yuyan Ding; Wai Lam; Jessica Leventhal; Feng Dai; Douglas L Rothman; Graeme F Mason; Robert S Sherwin
Journal:  Diabetes       Date:  2018-10-16       Impact factor: 9.461

4.  Hippocampal Neurochemical Profile and Glucose Transport Kinetics in Patients With Type 1 Diabetes.

Authors:  Petr Bednařík; Pierre-Gilles Henry; Amir Khowaja; Nathan Rubin; Anjali Kumar; Dinesh Deelchand; Lynn E Eberly; Elizabeth Seaquist; Gülin Öz; Amir Moheet
Journal:  J Clin Endocrinol Metab       Date:  2020-02-01       Impact factor: 5.958

5.  Metabolomic Assays of Postmortem Brain Extracts: Pitfalls in Extrapolation of Concentrations of Glucose and Amino Acids to Metabolic Dysregulation In Vivo in Neurological Diseases.

Authors:  Gerald A Dienel
Journal:  Neurochem Res       Date:  2018-08-16       Impact factor: 3.996

6.  Infusion of N-acetyl cysteine during hypoglycaemia in humans does not preserve the counterregulatory response to subsequent hypoglycaemia.

Authors:  Amir Moheet; Anjali Kumar; Yuan Zhang; Lynn Eberly; Lisa D Coles; Elizabeth R Seaquist
Journal:  Endocrinol Diabetes Metab       Date:  2020-05-15

Review 7.  Central Mechanisms of Glucose Sensing and Counterregulation in Defense of Hypoglycemia.

Authors:  Sarah Stanley; Amir Moheet; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

8.  Heterogeneity in Epinephrine Response to Experimental Hypoglycemia in Type 1 Diabetes and Controls.

Authors:  Yuan Zhang; Gülin Öz; Amir Moheet; Anjali Kumar; Alison Alvear; Silvia Mangia; Lynn Eberly; Elizabeth R Seaquist
Journal:  J Endocr Soc       Date:  2022-03-23

Review 9.  Experimentally Induced Hypoglycemia-associated Autonomic Failure in Humans: Determinants, Designs, and Drawbacks.

Authors:  Mads Bisgaard Bengtsen; Niels Møller
Journal:  J Endocr Soc       Date:  2022-08-09

10.  Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure.

Authors:  Eric Lontchi-Yimagou; Sandra Aleksic; Raphael Hulkower; Rebekah Gospin; Akankasha Goyal; Bryan Kuo; William G Mitchell; Jee Young You; Laxmi Upadhyay; Michelle Carey; Oana A Sandu; Ilan Gabriely; Harry Shamoon; Meredith Hawkins
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.